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The purpose of the study is to test the hypothesis that expression of cell cycle regulatory proteins p16
INK4a and pRb is significantly
associated with prognosis in ovarian carcinomas. We performed immunohistochemical analysis of p16
INK4a and pRb expression and
correlated with survival in a series of 300 patients with FIGO stage IIb-IV ovarian carcinoma which were enrolled in a randomized
prospective trial evaluating two different platinum and paxlitaxel chemotherapy combinations after radical surgery. p16
INK4a negative
tumours (17/300; 6%) had a significantly worse prognosis (univariate analysis, Po0.001; multivariate analysis: odds ratio 2.41,
P¼0.009). Among p16
INK4a-positive tumours (283 out of 300; 94%), survival was better for patients with intermediate expression as
compared to low or high expression levels (P¼0.001). High expression levels of pRb were associated with an incremental
deterioration of prognosis (univariate analysis, P¼0.004; multivariate analysis: odds ratio 2.98, P¼0.002). This observation held also
true in the subgroup of optimally debulked patients (n¼82), in whom the most important established prognostic factor,
postoperative residual tumour cannot be applied. In conclusion p16
INK4a and pRb are independent prognostic factors in advanced-
stage ovarian carcinomas after radical surgery and postoperative chemotherapy. High pRb expression is a significant prognosticator in
optimally debulked patients and may hold potential for subgroup stratification in postoperative treatment.
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State-of-the-art treatment of advanced-stage ovarian carcinoma
includes radical cytoreductive surgery aiming at the removal of all
visible tumour, followed by six cycles of platinum/paclitaxel (PT)
chemotherapy. The completeness of surgical tumour removal is
among the most powerful predictors of patient outcome (du Bois
et al, 2003). Currently, there are no additional generally accepted
prognostic markers independent from the established clinical
factors like International Federation of Gynaecology and Obstetrics
(FIGO) stage, postoperative residual tumour, patient age and
clinical performance status (Crawford et al, 2005).
The retinoblastoma (RB) regulatory pathway of cell cycle control
is deregulated in virtually all human tumour types (Cobrinik, 2005;
Korenjak and Brehm, 2005; Macaluso et al, 2005). In a
physiological cell state, the ability of the retinoblastoma protein
(pRb) to control cell cycle progression via binding members of the
E2F transcription factor family is controlled by cyclin D/cdk4-
mediated phosporylation. The p16
INK4a protein has been shown
to inhibit the phosphorylating activity of this functional cyclin
D/cdk4complex, thus abrogating the E2F-induced activation of
genes important for driving the cell cycle into S-phase progression.
Various specific genetic alterations of individual members of the
pRB-regulated pathway, including cyclin D, cdk4 and cyclin-
dependent kinase inhibitor p16
INK4a, contribute to the impairment
of cell cycle control at the G1 S-phase transition in different
tumour types. Deregulated expression of cell cycle promoting
cyclins, often resulting from specific tumour-associated gene
amplification, represents a common mechanism leading to loss
of cell cycle control, as well as genetic loss or transcriptional
downregulation of cellcycle inhibitory factors, for example pRb
and the CDK inhibitor p16
INK4a (Pei and Xiong, 2005; Sharpless,
2005). However, p16
INK4a expression has also been found to be
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sstrongly upregulated in certain neoplasms, such as cervical cancers
and cervical high-grade dysplasias (Klaes et al, 2001). In
proliferating cells from these cervical precancerous and cancerous
lesions, the E7 protein from high-risk human papillomaviruses
(HPV) inactivates the pRb–E2F transcription factor complex, thus
releasing the negative transcriptional control of the p16
INK4a gene
mediated by functional pRb–E2F complex. Besides its potential
utility as a diagnostic marker for the identification of cervical
lesions, overexpression of p16
INK4a has been reported to represent
a characteristic of mammary carcinomas associated with a poor
prognosis (Milde-Langosch et al, 2001).
Table 2 p16
INK4a and pRB immunostaining results and clinical prognostic factors vs survival of patients with ovarian carcinoma (univariate analysis)
Parameter Category Number Five-year survival (%) Median survival months (95%CI) P
All patients
p16
INK4a percentage of positive cells 0% 17 300 11.8 18.5 (7.2–29.7) 0.001
o10% 33 26.4 33.7 (29.0–33.5)
10–50% 69 40.7 45.8 (38.8–53.3)
51–80% 47 32.1 45.5 (37.4–53.6)
480% 134 31.2 39.0 (30.6–47.5)
p16
INK4a staining intensity Negative 17 300 11.8 18.5 (7.2–29.7) o0.001
Weak 31 39.6 35.5 (18.9–52.0)
Medium 134 37.3 44.6 (37.3–51.8)
Strong 118 26.0 35.4 (28.0–42.7)
p16
INK4a positive vs negative Negative 17 300 11.8 18.5 (7.2–29.7) o0.001
Positive 283 32.9 41.2 (35.5–46.8)
pRb percentage of positive cells 0% 8 300 57.1 66.0 (n.a.) 0.001
o10% 50 47.3 57.0 (39.4–74.6)
10–50% 97 37.2 45.2 (32.3–58.1)
51–80% 117 21.4 34.9 (26.1–41.9)
480% 28 15.3 27.1 (16.1–38.1)
pRb staining intensity Negative 8 300 57.1 66.0 (n.a.) 0.004
Weak 116 40.8 46.8 (39.9–53.7)
Medium 148 24.8 35.5 (31.5–39.4)
Strong 28 20.7 24.4 (15.3–33.6)
pRb low vs high Low 124 300 41.7 47.2 (37.8–56.6) 0.001
High 176 24.0 34.9 (29.4–40.5)
pRb positive vs negative Negative 8 300 57.1 66.0 (n.a.) 0.320
Positive 292 31.6 39.3 (34.3–44.4)
FIGO stage IIb-IIIa 35 300 64.5
a 0.001
IIIb/IV 265 27.8 37.0 (32.1–41.9)
Postoperative residual tumour 0 82 300 55.8 73.2 (43.6–102.8) o0.001
0–10mm 94 25.4 35.5 (26.6–44.3)
11+mm 124 21.0 32.3 (34.3–44.9)
Preoperative tumour size o10mm 48 292
b 42.3 57.0 (45.3–68.8) 0.017
410mm 244 29.1 35.6 (31.7–39.6)
Age o65yrs 217 300 32.8 43.5 (38.8–48.1) 0.030
465yrs 83 28.3 30.2 (22.4–38.0)
ECOG 0 133 300 38.8 46.7 (34.7–58.7) 0.004
40 137 26.3 34.9 (29.6–40.4)
Ki-S5 oMedian 147 295
c 25.3 35.3 (30.2–40.6) 0.011
4Median 148 39.0 45.6 (36.0–55.3)
Completely debulked patients
p16
INK4a positive vs negative Negative 4 82 50.0 34.3 (0.0–73.9) 0.227
Positive 78 56.1
a
pRb low vs high Low 34 82 68.8
a 0.009
High 48 46.1 44.0 (29.3–58.6)
Preoperative tumour size o 10mm 28 80
b 59.6
a 0.338
410mm 52 51.2 73.2 (36.0–110.4)
FIGO stage IIb-IIIa 26 82 70.0
a 0.195
IIIb/IV 56 50.3 73.2 (52.4–94.0)
Age (years) o 65years 61 82 55.6 73.2 (42.3–104.1) 0.319
465years 21 52.9
a
ECOG 0 46 82 57.5 73.2 (n.a.) 0.534
40 36 55.1
a
CI¼confidence interval; ECOG¼Eastern Cooperative Oncology Group; FIGO¼International Federation of Gynaecology and Obstetrics; pRb¼retinoblastoma protein.
aMedian survival could not be calculated, since o50% of patients were dead of disease at the time of analysis.
bMissing preoperative tumour size data for eight patients.
cExclusion
of five cases from further analysis for technical reasons.
Table 1 Histological types of ovarian carcinomas
Histological type n (%)
Serous 135 (45.0)
Mucinous 24 (8.0)
Endometrioid 57 (19.0)
Clear cell 37 (12.3)
Transitional cell 16 (5.3)
Undifferentiated 31 (10.3)
Total 300 (100.0)
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INK4a and pRb has been
investigated in various studies using immunohistochemistry
(Dong et al, 1997a,b; Niemann et al, 1998; Kusume et al, 1999;
Sui et al, 2000; Milde-Langosch et al, 2003; Raspollini et al, 2004;
Hashiguchi et al, 2004). However, the results from these studies
provided conflicting information concerning the expression of pRb
and p16
INK4a, and the prognostic significance of differential
expression levels of these cellcycle regulatory proteins in ovarian
carcinomas. Most of the previous studies are characterised by
either a relatively low number of cases analysed, or by a broad
heterogeneity with respect to stage and postoperative therapy,
or by only limited follow-up data being available. Therefore, this
study aimed to test the hypothesis that expression of cell-cycle
regulatory proteins p16
INK4a and pRb is significantly associated
with prognosis in a large, homogeneous series of advanced-stage
ovarian carcinomas receiving standardised chemotherapy after
radical surgery (du Bois et al, 2003).
MATERIALS AND METHODS
Study material
After completion of a prospective randomised, multi-centre, phase
III study of a total of 798 patients with ovarian cancer, FIGO-stages
IIB–IV, comparing cisplatin 75mgm
 2 plus 185mgm
 2 PT with
PT 185mgm
 2 plus carboplatin (TC) (du Bois et al, 2003), tissue
blocks were requested from participating centres for translational
research. Between one and 53 paraffin blocks per case were
received from a total of 334 study patients. An explorative
comparison of patient characteristics between patients with or
without available paraffin blocks was performed. Paraffin sections
were cut from all blocks and stained with Haematoxylin and Eosin.
After review of all slides and exclusion of material which contained
no tumour tissues, or which was insufficient for adequate
histopathological analysis (32 cases), between one and nine stained
sections each from a total of 300 cases of primary invasive
epithelial ovarian carcinomas were available for further studies.
All slides were reviewed by two experienced gynaecopathologists
(FK, DS) who were blinded for the outside diagnoses. All ovarian
carcinomas were typed according to the current WHO criteria and
classified as either serous, mucinous, endometrioid, clear cell,
transitional cell or undifferentiated carcinoma (Scully, 1999;
Tavassoli and Devilee, 2003).
Immunohistochemistry
Sections 2–4mm were cut from paraffin blocks, deparaffinised in
xylene and rehydrated. Antigen retrieval for p16
INK4a immuno-
staining was performed by incubating slides in 0.01 M citrate buffer
(pH 6.0) for 40min at 951C in a water bath (Pasha, Montone and
Tomaszewski, 1995), sections for pRb immunostaining in 0.1 M
sodium citrate buffer (pH 6.0) for 20min in a microwave oven
(Shi, Key and Kalra, 1991). For p16
INK4a immunostaining, mouse
monoclonal antibody clone E6H4 (mtm laboratories, Heidelberg,
Germany) was used. A polymer-horseradish peroxidase-based
secondary reagent system (Envisionþ, Dako A/S, Glostrup,
Denmark) was used for signal generation following the instruc-
tions of the manufacturer. For pRb-immunostaining, mouse
monoclonal antibody clone 3C8 (QED Bioscience Inc., San Diego,
CA, USA) (Wen et al, 1994) was used at a 1:450 dilution. Signal
generation was carried out following the VECTASTAIN
s ELITE
ABC KIT protocol (Vector Laboratories, Burlingame, CA, USA).
3,30-Diaminobenzidine hydrochloride was used as chromogen for
both immunostaining protocols, and slides were finally counter-
stained with Mayer ´s Hemalaun. Appropriate positive controls (for
p16
INK4a: cervical high-grade lesions (CIN III), for pRb: breast
cancer specimens) and negative reagent controls were included in
each staining run. Proliferation activity was measured immuno-
histochemically using monoclonal Ki-S5 antibody (kindly pro-
vided by R Parwaresch, Institute of Pathology, University of Kiel,
Germany) as described (Kreipe et al, 1993).
Evaluation of immunostains
p16
INK4a and pRb immunostaining intensities (ISI: no staining¼0;
weak staining¼1; medium staining¼2; strong staining¼3) and
percentages of positively stained cells (PPC: 0%¼0; o10%¼1;
10–50%¼2; 51–80%¼3; 480%¼4) were assessed for each
tumour. Negative and weak ISI were considered low pRb, mean
and strong ISI were considered high pRb. Proliferative activity as
measured by Ki-S5 immunostaining was calculated as percentage
of positive cells. Any unequivocal nuclear staining of neoplastic
epithelial tumour cells was considered specific.
For p16
INK4a evaluation, staining patterns of nuclear only,
cytoplasmatic only and combined nuclear/cytoplasmatic were
accepted as specific; for pRb any unequivocal nuclear staining of
epithelial tumour cells was considered specific. For evaluation
of Ki-S5 staining, the respective area showing the highest level of
proliferation for each tumour specimen was identified at low
A
B
H&E
H&E
Figure 1 Examples of immunohistochemistry, insets show haematoxylin
and eosin stains. (A)p 1 6
INK4a-positive ovarian carcinoma (PPC480%, ISI 3).
(B) pRb-positive ovarian carcinoma (PPC 51–80%, ISI 2).
p16
INK4a and pRb in advanced ovarian carcinoma
S Kommoss et al
308
British Journal of Cancer (2007) 96(2), 306–313 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smicroscopical power. Five-hundred tumour cells per slide were
then counted at a  400 magnification.
Statistical analysis
The exploratory analysis of possible selection bias of the study
population was performed by the w
2-test (Armitage and Berry,
1994). Survival analysis was performed according to the method of
Kaplan and Meier (Kaplan and Meier, 1958), survival times were
compared using the log rank test (Mantel, 1966) applying SPSS13
software (SPSS for Windows, Rel. 13.0.1., 2004). Multivariate
analyses were performed using the Cox regression (Cox, 1972).
RESULTS
From a randomised prospective trial of patients receiving
standardised postoperative chemotherapy after radical surgery,
300 cases of primary invasive epithelial ovarian carcinoma were
selected without following any rule, other than being dependent on
availability of material and willingness to cooperate. No significant
selection bias was found after explorative analysis of patient
characteristics (patient age, Eastern Cooperative Oncology Group
(ECOG) clinical performance status, FIGO stage, preoperative
extraovarian tumour, postoperative residual tumour) comparing
patients with and without available paraffin blocks by w
2-analysis
(data not shown). The distribution of histological types of ovarian
carcinomas according to current WHO criteria after central review
of H&E-stained re-cuts from all available paraffin blocks is shown
in Table 1.
Both p16
INK4a and pRb immunostains of sufficient quality were
available for further analysis from a total of 300 cases. Most cases
were p16
INK4a-positive (283 out of 300; 94%), likewise a majority
of cases showed some pRb immunoreactivity (292 out of 300;
97%), ISI and PPC for p16
INK4a and pRb, respectively, are given in
Table 2. Examples for staining results are given in Figure 1. ISI and
PPC were closely covariant (Po0.0001) for both markers. p16
INK4a
and pRb expression levels were found to be independent from the
established prognostic factors FIGO stage, postoperative residual
tumour and age (Tables 3a and 3b). A statistically significant,
however weak, negative correlation between p16
INK4a and pRb PPC
was observed (correlation coefficient PPC:  0.114, P¼0.01; ISI:
 0.091, P¼0.08). Kaplan–Meier survival estimates showed a
significantly worse prognosis for p16
INK4a-negative patients
(Po0.001; Table 2, Figure 2A). p16
INK4a-negative tumours were
of no particular histological type. p16
INK4a staining results were
independent from established prognostic markers (Table 3a).
Among p16
INK4a-positive tumours (283 out of 300; 94%), survival
Table 3a Patient characteristics (all patients): p16
INK4a positive vs p16
INK4a negative
p16
INK4a Negative p16
INK4a Positive Total
Parameters Category n % n % n % v
2-test
Tumour postop 0mm 4 23.5 78 27.6 82 27.3 P¼0.911
1–10mm 6 35.3 88 31.1 94 31.3
410mm 7 41.2 117 41.3 124 41.3
Tumour preop
a o1cm 4 26.7 44 15.9 48 16.4 P¼0.272
41cm 11 73.3 233 84.1 244 83.6
Age o 65 years 9 52.9 208 73.5 217 72.3 P¼0.066
465 years 8 47.1 75 26.5 83 27.7
FIGO stage IIb–IIIa 3 17.6 32 11.3 35 11.7 P¼0.429
IIIb–IV 14 82.4 251 88.7 265 88.3
ECOG 0 5 29.4 128 45.2 133 44.3 P¼0.202
40 12 70.6 155 54.8 167 55.7
ECOG¼Eastern Cooperative Oncology Group; FIGO¼International Federation of Gynaecology and Obstetrics; pRb¼retinoblastoma protein.
aMissing preoperative tumour
size data for eight patients.
Table 3b Patient characteristics (optimally debulked patients): low pRb vs high pRb
Low pRb High pRb Total
Parameters Category n % n % n % v
2-test
Tumour preop
a o1cm 12 36.4 16 34.0 28 35.0 P¼0.830
41cm 21 63.6 31 66.0 52 65.0
Age o65 years 24 70.6 37 77.1 61 74.4 P¼0.507
465 years 10 29.4 11 22.9 21 25.6
FIGO stage IIb–IIIa 9 26.5 17 35.4 26 31.7 P¼0.391
IIIb–IV 25 73.5 31 64.6 56 68.3
ECOG 0 20 58.8 26 54.2 46 56.1 P¼0.675
40 14 41.2 22 45.8 36 43.9
ECOG¼Eastern Cooperative Oncology Group; FIGO¼International Federation of Gynaecology and Obstetrics; pRb¼retinoblastoma protein.
aMissing preoperative tumour
size data for two patients.
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swas better for patients with intermediate expression as compared
to low or high expression levels (P¼0.001; Table 2). Furthermore,
p16
INK4a expression levels were associated with Ki-S5 proliferation
activity. Proliferation activity was higher in ovarian carcinomas
with either negative or strong p16
INK4a expression, compared to
cases with only weak or moderate expression levels (Figure 3).
Within the subgroups of p16
INK4a-negative and p16
INK4a-positive
carcinomas, patients with low proliferation activity as measured by
Ki-S5 immunostaining had a lower median survival as compared
to those with a high proliferation (p16
INK4anegative, Ki-S5 low:
11.1 months, Ki-S5 high: 20.4 months; p16
INK4apositive, Ki-S5 low:
37.2 months, Ki-S5 high: 46.9 months) activity (Figure 2B).
Immunohistochemical pRb expression analysis revealed an
incremental deterioration of prognosis with increasing pRb ISI
(P¼0.004, Table 2, Figure 2C and D), as well as pRb PPC
(P¼0.001, Table 2). pRb protein expression levels were not
associated with Ki-S5 proliferation activity (data not shown).
The results of further univariate analyses of established clinical
prognosticators are shown in Table 2. Multivariate analysis
including FIGO stage, postoperative residual tumour, ECOG
performance status, age and Ki-S5 proliferation activity, estab-
lished an independent prognostic significance of both pRb ISI
(odds ratio: 2.98, P¼0.002) and p16
INK4a expression (odds ratio
2.41, P¼0.009 (Table 4).
For the subgroup of nonoptimally debulked patients (P¼0,015,
Figure 2E), as well as for the subgroup of optimally debulked
patients (P¼0.009, Table 2, Figure 2F), pRb ISI was still found to
be a significant prognosticator. Of note, no prognostic information
could be derived from the established factors in the latter
subgroup. In contrast to pRb ISI, pRb PPC (P¼0.21) as well as
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Figure 2 (A) Kaplan–Meier survival estimates showed a worse prognosis for p16
INK4a-negative patients (n¼17/300; Po0.001). (B) Among both
p16
INK4a-negative and p16
INK4a-positive carcinomas, low Ki-S5 proliferation activity was associated with a worse prognosis as compared to high proliferation
activity. (C) Incremental deterioration of prognosis with increasing pRb ISI (P¼0.004). (D) Patients with high pRb expression (¼medium and high ISI,
n¼176) had a worse prognosis as compared to patients with low pRb expression (¼negative and low ISI, n¼124) P¼0.001. (E) Survival curve for the
nonoptimally debulked group (n¼218; P¼0.015). (F) In the subgroup of optimally debulked patients, high pRb indicated a significantly worse prognosis
(n¼82; P¼0.009).
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INK4a ISI (P¼0.49) and PPC (P¼0.25) were not associated
with prognosis in this group of optimally debulked ovarian cancer
patients.
DISCUSSION
In this retrospective study, the prognostic significance of
established prognostic factors in ovarian carcinoma was confirmed
in a large, uniform treated group of patients with advanced-stage
ovarian carcinoma. In addition, an independent prognostic
significance of p16
INK4a and pRb expression was observed.
Patients with p16
INK4a-negative tumours had a significantly
worse prognosis as compared to patients with p16
INK4a-positive
carcinomas. Interestingly, the evaluation of p16
INK4a expression
levels as measured by both ISI and PPC provided further
prognostic information among the group of p16
INK4a-positive
patients. While survival was optimal among patients showing
intermediate p16
INK4a expression levels in the tumour tissue, a
worse prognosis was observed both in patients with low, as well as
with high p16
INK4a expression levels. These observations might
indicate that loss of cell cycle control characterised by a complete
lack of p16
INK4a expression defines a relatively small, but distinct
subgroup of advanced-stage ovarian cancer patients with an
unfavourable prognosis. Furthermore, similar to the situation in
cervical cancer, strong upregulation of p16
INK4a protein expression
obviously reflects a subset of tumours in which the p16
INK4a-
mediated control of cell cycle progression by regulation of the
phosphorylation status of pRb is bypassed by genetic alterations of
other essential components of the cell cycle control machinery.
Whereas in cervical cancer strong p16
INK4a overexpression can be
observed in virtually all high-grade dysplastic and cancerous cases
as a consequence of functional inactivation of pRb by the E7
protein of high-risk HPV, high p16
INK4a protein levels characterise
only a subgroup of patients with advanced-stage ovarian cancers
associated with a worse prognosis.
In this series, proliferative activity as defined by Ki-S5
immunohistochemistry (Kreipe et al, 1993) has been show to be
of independent prognostic significance (Kommoss et al, 2006).
Interestingly, high proliferative activity was observed in tumours
completely lacking p16
INK4a expression as well as in those showing
strong p16 immunoreactivity (Figure 3). In the subgroups of
patients with p16
INK4a-negative and p16
INK4a-positive cancers, the
numbers of high- and low-proliferative tumours as assessed by
Ki-S5 immunostaining (Kreipe et al, 1993) were evenly distributed
(p16
INK4a -negative, Ki-S5 low: n¼8, Ki-S5 high: n¼8; p16
INK4a -
positive, Ki-S5 low: n¼139; Ki-S5 high: n¼140), thus further
validating the finding that lack of p16
INK4a expression represents
an independent strong negative prognostic factor in patients with
advanced-stage ovarian cancers, independent from other key
characteristics of cancer cells, as for example, proliferative activity
(Tables 3a and 3b). In both latter subgroups, patients with low
proliferation had a lower median survival as compared to those
with high proliferation, and a p16
INK4a-negative/low proliferation
phenotype was associated with the worst prognosis (Figure 2B).
Conflicting results concerning the prognostic impact of p16
INK4a
expression in ovarian carcinoma have been reported in the past.
While no prognostic significance of p16
INK4a immunoreactivity
was described by Milde-Langosch et al (2003), Sui et al (2000), as
well as by Kusume et al (1999), other reports suggested that high
levels of p16
INK4a expression predict poor prognosis (Dong et al,
1997a). These contrary findings may be due to inherent limitations
of some of the previously published studies. While the present
collective contains only advanced-stage patients receiving stan-
dardized chemotherapy (du Bois et al, 2003), series comprising
both early and advanced FIGO stages were analysed by others
(Dong et al, 1997a,b; Niemann et al, 1998; Kusume et al, 1999; Sui
et al, 2000; Milde-Langosch et al, 2003; Hashiguchi et al, 2004).
Postoperative therapy was either variable (Dong et al, 1997b;
Kusume et al, 1999; Milde-Langosch et al, 2003; Hashiguchi
et al, 2004) or not mentioned (Dong et al, 1997a; Sui et al, 2000).
Furthermore, case numbers were limited in many of the previous
reports (some authors reporting o50 cases (Raspollini et al, 2004;
Niemann et al, 1998). Finally, the comparison of survival data is
complicated by the use of various cutoff values for the assessment
of p16
INK4a expression levels in previous publications.
The assessment of ISI and PPC as used in this study has also
been applied in some previous studies (Lamperska et al, 2002;
Milde-Langosch et al, 2003). However, there is still substantial
heterogeneity when it comes to a definition of specific cutoff values
that are used for the respective scoring of immunoreactivities, thus
limiting the comparability of results.
The inverse correlation of p16
INK4a and pRb expression levels
in our study is in line with the physiological regulation of
transcription of these two tumour suppressor genes. Transcription
from the p16
INK4a promoter is suppressed by functional pRb (Li
et al, 1994), whereas expression of functional p16
INK4a induces
downregulation of pRb transcription (Fang et al, 1998).
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Figure 3 Correlation between p16
INK4a expression and proliferative
activity as measured by Ki-S5 immunohistochemistry.
Table 4 Survival of patients with ovarian carcinoma, multivariate analysis
Parameter Category Number OR (95% CI) P
FIGO stage IIb–IIIa 35 300 1 0.003
IIIb/IV 265 2.45 (CI 1.28–4.69)
Postoperative residual
tumour
0 82 300 1 o0.001
0–10mm 94 2.04 (1.33–3.14)
410mm 124 2.27 (1.50–3.44)
p16
INK4a staining Negative 17 300 2.41 (1.30–4.46) 0.009
Positive 283 1
pRb intensity Negative 8 300 1 0.002
Weak 116 1.39 (0.50–3.86)
Medium 148 2.42 (0.88–6.70)
Strong 28 2.98 (0.96–9.24)
Age (years) o65 217 300 1 0.018
465 83 1.50 (1.08–2.07)
Ki-S5 oMedian 147 295
a 1.62 (1.22–2.18) 0.001
4Median 148 1
CI¼confidence interval; FIGO¼International Federation of Gynaecology and
Obstetrics; OR¼odds ratio; pRb¼retinoblastoma protein.
aExclusion of five cases
from further analysis for technical reasons.
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significantly associated with a worse prognosis in the homogenous
group of patients with advanced-stage ovarian cancers.
Our findings confirm the results of a previous study suggesting a
potential association of high pRb expression with decreased
survival (Milde-Langosch et al, 2003). In addition, our analysis
suggested that low pRb expression levels may still be associated
with a significantly superior survival in the subgroup of
optimally debulked patients: five-year survival rates for
patients with low pRb expression were 68.8%, compared to
46.1% survival rates in patients characterised by high pRb
expression levels.
Of note, Dong et al. (1997b) found the prognosis to be worse
in FIGO stage I tumours with low pRb expression. In that study,
high expression levels of pRb were reported in advanced-stage
carcinomas; however, no prognostic significance of pRb expres-
sion was reached for that subgroup. These findings further
support the relevance of using uniform groups of patients
characterised by defined sets of tumours, as well as consistent
treatment regimens and follow-up schedules when analysing the
potential value and clinical relevance of prognosticators of
postoperative disease.
This study is limited by case numbers, especially in clinically
important subgroups. Although thorough statistical analysis of
the study population was performed, a selection bias cannot be
completely ruled out.
Further evaluation using prospective study protocols will
have to be performed to validate the results obtained in this
retrospectively performed analysis. If confirmed, our findings
may be of interest for clinical practice. Optimally debulked
patients have a much better prognosis as compared to patients
with residual tumour (du Bois et al, 2003). However, a significant
proportion of patients will relapse and finally die even in this
favorable subgroup. Recently, complex gene expression profiles
have been described as providing independent prognostic
information in advanced stage ovarian cancer. Patients showing
an unfavourable gene signature had a significantly worse
prognosis. Although a similar trend was observed among
optimally debulked patients, the prognostic impact did not reach
statistical significance (Spentzos et al, 2004, 2005). Thus far it
has not been possible to further subdivide completely
debulked patients into prognostic subgroups. However, tools
to identify different prognostic subgroups in this cohort might
offer the opportunity for further clinical studies of aggressive
maintenance therapy. The results of our study suggest that if
the current findings are confirmed prospectively, the assessment of
p16
Ink4a and pRb expression levels may prove to be a useful
prognostic factor in advanced-stage ovarian carcinomas after
standardised chemotherapy including completely debulked
patients.
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